Indications |
Oral Painful muscle spasm associated with musculoskeletal conditions Adult: Initially, 500 mg 3-4 times daily, may subsequently reduce to 250 mg 3-4 times daily. Max: 750 mg 3-4 times daily. |
Contraindications |
Hypersensitivity. Liver disease. Porphyria. Lactation. |
Warnings / Precautions |
Pregnancy, known allergies. Tasks requiring mental alertness may be impaired. Monitor liver function. |
Adverse Reactions |
Drowsiness, dizziness, lightheadedness, headache, excitement, restlessness, GI disturbances, irritability, sensitivity reactions (skin rash). Jaundice, liver damage reported. Orange or reddish-purple urine. Potentially Fatal: Anaphylactoid reactions, angioedema, fatal hepatocellular toxicity. |
Drug Interactions |
Potentially Fatal: Additive effect when used with other CNS depressants or alcohol. See Below for More chlorzoxazone Drug Interactions |
Food Interactions |
Additive CNS effects when taken with alcohol. |
Mechanism of Actions |
Chlorzoxazone acts at the level of the spinal cord and subcortical areas of the brain where it inhibits multisynaptic areas involved in producing and maintaining skeletal muscle spasm of varied etiology, thus relieving painful musculoskeletal conditions. It also has sedative property. Onset: 1 hr. Duration: 3-4 hr. Absorption: Completely absorbed from the GI tract (oral); peak plasma concentrations after 1-2 hr. Metabolism: Hepatic; yielding 6-hydroxychlorzoxazone. Excretion: Via urine (mainly as glucuronide); 1 hr (elimination half-life). |
Administration |
Should be taken with food. |
Storage Conditions |
Oral: Store at 15-30°C. |
ATC Classification |
M03BB03 - chlorzoxazone ; Belongs to the class of oxazol, thiazine, and triazine derivative agents. Used as centrally-acting muscle relaxants. |
Storage |
Oral: Store at 15-30°C. |
Available As |
|
Chlorzoxazone
Post Review about Chlorzoxazone Click here to cancel reply.
Chlorzoxazone Containing Brands
Chlorzoxazone is used in following diseases
Drug - Drug Interactions of Chlorzoxazone
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.